The current NZ Sanofi levomepromazine (Nozinan®) 25 mg and 100 mg tablets will be replaced with Swiss Sanofi Nozinan® formulations temporarily from 1st March 2020. They are not bioequivalent.

Transition requires a review of the prescription for individual patients, and monitoring for altered clinical effect or toxicity. For more information, see our bulletin or www.medsafe.govt.nz.